8. Cho SY, Lee DG, Kim HJ. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. International
journal of molecular sciences 2019; 20(11).
9. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 2009; 15(10):
1143-1238.
10. Carreras E, Dufour C, Mohty M, Kroger N. The EBMT Handbook:
Hematopoietic Stem Cell Transplantation and Cellular Therapies: European Blood and Marrow Transplant Group; 2019.
11. Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious diseases 2019; 19(8): e260-e272.
12. Baden LR, Swaminathan S, Almyroudis NG, et al. NCCN Clinical Practice Guideline in Oncology: Prevention and Treatment of Cancer-Related Infections, Version 1. 2019. National Comprehensive Cancer Network.
https://www.nccn.org/professionals/physician_gls/default.aspx. Published 2018.
Accessed August 1, 2019.
13. ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.
https://www.whocc.no/atc_ddd_index/?code=J05AX. Published 2019. Accessed August 9, 2019.
14. 西藥、醫療器材、特定用途化妝品許可證查詢. 衛生福利部食品藥物管理署.
https://www.fda.gov.tw/MLMS/H0001.aspx. Published 2019. Accessed August 9, 2019.
15. 全民健康保險藥物給付項目及支付標準之藥品給付規定-108 年版. 衛生福 利部中央健康保險署.
https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC 7D09599D25979. Published 2019. Accessed August 13, 2019.
16. CADTH Canadian Drug Expert Committee Recommendation (Final):
Letermovir (Prevymis-Merck Canada Inc.). Common Drug Review, Canadian Agency for Drugs and Technologies in Health. https://www.cadth.ca/letermovir.
Published 2019. Accessed July 31, 2019.
17. Letermovir: Tablet 240 mg; Prevymis - Public Summary Document (PSD) July 2018 PBAC Meeting. The Pharmaceutical Benefits Scheme.
http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2018-07/
Letermovir-psd-july-2018. Published 2018. Accessed July 31, 2019.
18. Letermovir: Tablet 240 mg; Prevymis - Public Summary Document (PSD) March 2019 PBAC Meeting. The Pharmaceutical Benefits Scheme.
http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2019-03/
letermovir-psd-march-2019. Published 2019. Accessed July 31, 2019.
19. Letermovir for preventing cytomegalovirus disease after a stem cell transplant:
technology appraisal guidance [TA591]. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta591. Published 2019. Accessed July 31, 2019.
20. Letermovir 240 mg film-coated tablets (Prevymis): SMC No. 1338/18. Scottish Medicines Consortium.
https://www.scottishmedicines.org.uk/medicines-advice/letermovir-prevymis-full submission-133818/. Published 2019. Accessed July 31, 2019.
21. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. The New England
journal of medicine 2017; 377(25): 2433-2444.
22. Gagelmann N, Ljungman P, Styczynski J, Kroger N. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 2018; 24(10):
2101-2109.
23. Ljungman P, Schmitt M, Marty FM, et al. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America 2019.
24. Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C. Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult
cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy. Infection and drug resistance 2019; 12:
1127-1138.
25. Lin HC, Han SM, Hwang WL, et al. Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area. Turkish journal of haematology :
official journal of Turkish Society of Haematology 2017; 34(2): 159-166.
26. 2018 年台灣肺炎指引. 台灣感染症醫學會、台灣胸腔重症加護醫學會、財團 法人鄭德齡依學發展基金會. https://pneumonia.idtaiwanguideline.org.
Published 2018. Accessed August 7, 2019.
附錄
附錄一 療效評估文獻搜尋記錄 PubMed
查詢日期 編號 關鍵字 篇數
2019/7/26
#1 "AIC246"[Supplementary Concept] OR "AIC246"[All Fields]
OR "letermovir"[All Fields] 115
#2
"cytomegalovirus infections"[MeSH Terms] OR ("cytomegalovirus"[All Fields] AND "infections"[All Fields]) OR "cytomegalovirus infections"[All Fields] OR ("cytomegalovirus"[All Fields] AND "infection"[All Fields]) OR
"cytomegalovirus infection"[All Fields]
37783
#3
"haematopoietic stem cell transplantation"[All Fields] OR
"hematopoietic stem cell transplantation"[MeSH Terms] OR ("hematopoietic"[All Fields] AND "stem"[All Fields] AND
"cell"[All Fields] AND "transplantation"[All Fields]) OR
"hematopoietic stem cell transplantation"[All Fields]
59417
#4
"bone marrow transplantation"[MeSH Terms] OR ("bone"[All Fields] AND "marrow"[All Fields] AND "transplantation"[All Fields]) OR "bone marrow transplantation"[All Fields]
90129
#5 #1 AND #2 AND (#3 OR #4) 37
#6 #5 AND (Randomized Controlled Trial[ptyp] OR systematic[sb]
OR Meta-Analysis[ptyp]) 3
Cochrane Library
查詢日期 編號 關鍵字 篇數
2019/7/26
#1 Letermovir 24
#2 MeSH descriptor: [Cytomegalovirus Infections] explode all trees 737
#3 MeSH descriptor: [Hematopoietic Stem Cell Transplantation]
explode all trees 1297
#4 #1 and #2 and #3 2
Embase
查詢日期 編號 關鍵字 篇數
2019/7/26
#1 'letermovir'/exp OR letermovir 246
#2 'cytomegalovirus infection'/exp OR 'cytomegalovirus infection' 41350
#3 hematopoietic stem cell transplantation'/exp OR 'hematopoietic
stem cell transplantation' 64040
#4 #1 AND #2 AND #3 64
#5 #4 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) 8
附錄二、經濟評估文獻搜尋記錄 PubMed
查詢日期 編號 關鍵字 篇數
2019/8/12
#1
[Letermovir]
"AIC246"[Supplementary Concept] OR "AIC246"[All Fields] OR "letermovir"[All Fields]
120
#2
[(cost effectiveness analysis) OR (cost benefit analysis) OR (cost utility analysis) OR (cost minimization analysis)]
("cost-benefit analysis"[MeSH Terms] OR
("cost-benefit"[All Fields] AND "analysis"[All Fields]) OR
"cost-benefit analysis"[All Fields] OR ("cost"[All Fields]
AND "effectiveness"[All Fields] AND "analysis"[All Fields]) OR "cost effectiveness analysis"[All Fields]) OR ("cost-benefit analysis"[MeSH Terms] OR
("cost-benefit"[All Fields] AND "analysis"[All Fields]) OR
"cost-benefit analysis"[All Fields] OR ("cost"[All Fields]
AND "benefit"[All Fields] AND "analysis"[All Fields]) OR
"cost benefit analysis"[All Fields]) OR ("cost-benefit
analysis"[MeSH Terms] OR ("cost-benefit"[All Fields] AND
"analysis"[All Fields]) OR "cost-benefit analysis"[All Fields] OR ("cost"[All Fields] AND "utility"[All Fields]
AND "analysis"[All Fields]) OR "cost utility analysis"[All Fields]) OR ("costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields] AND "cost"[All Fields] AND
"analysis"[All Fields]) OR "costs and cost analysis"[All Fields] OR ("cost"[All Fields] AND "minimization"[All Fields] AND "analysis"[All Fields]) OR "cost minimization analysis"[All Fields])
254,331
#3 #1 AND #2 2